Padcev Receives Regular FDA Approval for Locally Advanced or Metastatic Urothelial Cancer

August 2021 Vol 14, Special Issue: Payers' Perspectives in Oncology - FDA Approvals, Urothelial Cancer, Conference Highlights ASCO

On July 9, 2021, the FDA granted full approval to enfortumab vedotin-ejfv (Padcev; Astellas Pharma), a Nectin-4–directed antibody and microtubule inhibitor conjugate, for the treatment of adults with locally advanced or metastatic urothelial cancer who have previously received a PD-1 or PD-L1 inhibitor and platinum-containing chemotherapy, or who are ineligible for cisplatin-containing chemotherapy and have received ≥1 previous lines of therapy. The FDA granted initial accelerated approval to enfortumab vedotin for this indication in December 2019.

The current regular FDA approval of enfortumab vedotin for this indication was based on the results of the EV-301 clinical trial, an open-label, randomized, multicenter study that was conducted to further confirm the clinical benefit of enfortumab vedotin for this indication, as part of the requirements of the initial accelerated approval.

Related Items
Retevmo Receives New FDA Indication for Advanced Solid Tumors with RET Fusion
Web Exclusives published on November 30, 2022 in FDA Approvals
Imbruvica Now Also Indicated for Children with Chronic Graft-versus-Host Disease
Web Exclusives published on November 17, 2022 in FDA Approvals
Pemazyre Receives New Indication for FGFR1-­Positive Myeloid/Lymphoid Neoplasms
Web Exclusives published on November 17, 2022 in FDA Approvals
Vegzelma a New Biosimilar FDA Approved for the Treatment of 6 Types of Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Enhertu First FDA-Approved Drug for HER2-Positive Non–Small-Cell Lung Cancer
Web Exclusives published on October 31, 2022 in FDA Approvals
Last modified: August 30, 2021
Copyright © Engage Healthcare Communications, LLC. All rights reserved.